ESR1 and breast carcinoma: Tamoxifen is an ER antagonist in the breast, and it is sometimes prescribed to reduce risk among women with higher risk of breast cancer, including in women with dense breasts, and it is a first-line treatment to prevent breast cancer recurrence [180, 182].